Bupivacaine

Generic Name: Bupivacaine

Brand Names: Exparel, Kenalog, Marbeta, Marcaine, Marcaine With Epinephrine, Marvona Suik, P-Care M, P-Care MG, P-care, Posimir, Readysharp Anesthetics Plus Ketorolac, Readysharp-A, Readysharp-p40, Readysharp-p80, Sensorcaine, Sensorcaine With Epinephrine, Vivacaine, Xaracoll, Exparel liposomal

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₈N_₂O

CAS Number: 38396-39-3

Unique Ingredient Identifier: Y8335394RO

Background: Bupivacaine is a widely used local anesthetic agent.

Indication: As an implant, bupivacaine is indicated in adults for placement into the surgical site to produce postsurgical analgesia for up to 24 hours following open inguinal hernia repair.

Bupivacaine, in liposome suspension, is indicated in patients aged 6 years and older for single-dose infiltration to produce postsurgical local analgesia. In adults, it is also indicated as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.

Bupivacaine, in combination with meloxicam, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Bupivacaine, alone or in combination with epinephrine, is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations are recommended for each type of block indicated to produce local or regional anesthesia or analgesia. Finally, its use is not indicated in all blocks given clinically significant risks associated with use.

Associated Conditions: Acute Gouty Arthritis, Adrenocortical Insufficiency, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Berylliosis, Bullous dermatitis herpetiformis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatomyositis (DM), Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Hemolytic Anemia, Hypercalcemia caused by Cancer, Keloids Scars, Leukemias, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Ocular Inflammation, Ophthalmia, Sympathetic, Osteoarthritis (OA), Pain, Labor, Polymyositis, Postoperative pain, Psoriatic Arthritis, Psoriatic plaque, Pure Red Cell Aplasia, Regional Enteritis, Rheumatoid Arthritis, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Acute Bursitis, Acute Idiopathic Nephrotic Syndrome, Acute Lupus Erythematosus, Acute Multiple sclerosis, Acute Rheumatic heart disease, unspecified, Acute nonspecific tenosynovitis, Cystic tumors of aponeurosis, Cystic tumors of tendon, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Inflammatory lesions of granuloma annulare, Inflammatory lesions of lichen planus, Inflammatory lesions of lichen simplex, Non-suppurative Thyroiditis, Permphigus, Severe Allergic Reactions

Associated Therapies: General Anesthesia, Local Anaesthesia therapy, Regional nerve block therapy

Clinical Trials

Liposomal Bupivacaine Intercostal Nerve Block vs Thoracic Epidural for Regional Analgesia in Multiple Rib Fractures

Phase 4

Conditions: Trauma
Trauma Injury
Pain, Acute

Interventions: Drug: Bupivacaine Liposome Injection
Drug: Bupivacaine

First Posted Date: 2018-07-02

Last Posted Date: 2020-03-09

Lead Sponsor: Chadrick Evans

Target Recruit Count: 258

Registration Number: NCT03574376

Locations: 🇺🇸
Osf St Francis Medical Center, Peoria, Illinois, United States

Local Wound Infiltration Versus Caudal Block on Wound Infection and Healing in Paediatrics Inguinal Herniotomy

Not Applicable

Completed

Conditions: Healing Surgical Wounds

Interventions: Procedure: Caudal block
Procedure: Wound infiltration
Drug: Bupivacaine

First Posted Date: 2018-06-20

Last Posted Date: 2018-12-11

Lead Sponsor: University of Alexandria

Target Recruit Count: 50

Registration Number: NCT03563625

Locations: 🇪🇬
Alexandria Faculty of Medicine, Alexandria, Egypt

Wound Infiltration as Part of an Opioid Free Pain Management Pathway Following Cesarean Delivery

Phase 2

Conditions: Pain, Postoperative
Opioid Use
Anesthesia, Local

Interventions: Drug: Placebo
Drug: Bupivacaine
Drug: Dexmedetomidine

First Posted Date: 2018-06-04

Last Posted Date: 2018-08-29

Lead Sponsor: Richmond University Medical Center

Target Recruit Count: 540

Registration Number: NCT03545516

Locations: 🇺🇸
Richmond University Medical Center, Staten Island, New York, United States

Exparel vs. Bupivacaine Hydrochloride vs. Placebo for Hernia Repair

Phase 4

Completed

Conditions: Analgesia, Postoperative

Interventions: Drug: Placebo
Drug: Exparel
Drug: Bupivacaine Hcl 0.25% Inj

First Posted Date: 2018-05-31

Last Posted Date: 2021-10-12

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 164

Registration Number: NCT03541941

Locations: 🇺🇸
Cleveland Clinic Comprehensive Hernia Center, Cleveland, Ohio, United States

Safety and Activity of F14 for Management of Pain Following Total Knee Replacement

Phase 2

Completed

Conditions: Total Knee Replacement
Postoperative Pain

Interventions: Drug: Bupivacaine HCl
Drug: F14 (celecoxib)

First Posted Date: 2018-05-30

Last Posted Date: 2020-07-10

Lead Sponsor: Arthritis Innovation Corporation

Target Recruit Count: 20

Registration Number: NCT03541655

Locations: 🇺🇸
Panorama Orthopedics & Spine Center, Denver, Colorado, United States
🇺🇸
Endeavor Clinical Trials, San Antonio, Texas, United States
🇺🇸
Midwest Clinical Research Center, Dayton, Ohio, United States